Lab-on-a-Chip Technology


How it Works



Giant magnetoresistance (GMR) Working Principles

The electrical resistance of a metallic structure with several nanometers non-magnetic conducting thin film (e.g. copper) sandwiched between two ferromagnetic layers changes depending on the relative magnetization direction of the ferromagnetic layers.

Parallel magnetization results in lower resistance, while anti-parallel magnetization results in higher resistance. This phenomenon facilitates detection of stray fields from magnetic materials at nanometer scales.

A bead with magnetic nanoparticles added to a standard assay changes the local magnetization of a ferromagnetic layer in the GMR structure, which can be detected as a small change in resistance.



Bio-Surface And Magnetic Nanoparticles Bead Integration


Zepto Life’s on-chip bio-surface technology holds the capture antibodies in place. The bio-surface on the nanomagnetic particles allows them to be pre-labeled with detection antibodies. Analyte biomarkers are sandwich and specifically bound by capture and detection antibodies. Nanomagnetic particles would be attracted onto sensor surface and signal is read out real-time. Each biosensor is dedicated to a single biomarker.


Multiplex and Scalable

The multiple biosensors on a biochip is designed to deliver clinical results of a central laboratory at a point-of-care setting.
Each biochip is able to simultaneously detect and quantify multiple biomarkers.


Fully-Automated Assay

The disposable test cartridge uses microfluidics and on-chip bio-surface technologies to detect target antigens or antibodies from the microliter blood sample and immunoassay. The small channels are designed to decrease the assay time and increase assay automation.


Our First Product


Prototype at development phase


Portable Cardiac Reader and D-Dimer Test Cartridge


Zepto Life’s D-Dimer Assay is an automated magneto-immunoassay for the quantitative determination of D-Dimer in human whole blood and citrated plasma on the Zepto Reader for use, in conjunction with a clinical pretest probability (PTP) assessment model, to exclude venous thromboembolism (VTE) in patients suspected of deep venous thrombosis (DVT) and pulmonary embolism (PE). Our first product is designed as an in-vitro diagnostic to be used in a point-of-care setting.

Key product features serve point-of-care and point-of-need requirements:

  • Lab-equivalent assay performance. Same indication.
  • Fully automated assay.
  • Whole blood and citrated plasma.
  • Portable device in POC setting.
  • Fast turnaround time.
  • Seamless integration with existing LIS and EMR.
How can we help you?

Send us a message.